Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort
Authors:
Open Access
- 30 April 2024
- journal article
- research article
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 14 (2) , e2024152
Abstract
Introduction: Data about the long-term effectiveness of brodalumab could be valuable in assessing patient adherence to treatment and improving psoriasis management. Objective: The aim of our study was to evaluate the drug survival of brodalumab and identify any predictive factors for discontinuation. Methods: A multicenter retrospective study was conducted in patients with moderate-to-severe psoriasis who were treated for up to 3 years. We extracted data from patient files, related to the characteristics of the patients and the disease. Drug survival analysis was descriptively analyzed using Kaplan–Meier survival curves. Univariable and multivariable analyses were performed to assess baseline patient characteristics that predicted clinical response. Results: The study included 90 patients. Among them, 28 (31.1%) suspended brodalumab through the observation period. At weeks 52, 104 and 156 the median PASI score were 0.0 [0.0 – 0.8], 0.0 [0.0 – 1.0] and 0.0 [0.0 – 0.0], respectively. The estimated cumulative survival rates at weeks 52 and 104 were 86.32% and 78.09%, respectively. In the multivariable survival analysis, predictor factors for overall discontinuation included body mass index (BMI) (OR 1.10, 95% CI 1.03 - 1.18), baseline PASI (OR 1.06, 95% CI 1.02 - 1.10), and psoriatic arthritis (OR 5.05, 95% CI 0.89 - 13.50). Conclusions: Brodalumab has shown long-term effectiveness for up to 3 years. Considering baseline disease severity and patient characteristics could aid in optimizing the long-term management of psoriasis.Keywords
This publication has 35 references indexed in Scilit:
- Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic ArthritisDrugs in R&D, 2023
- Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort StudyJournal of Investigative Dermatology, 2023
- Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative ReviewDermatology and Therapy, 2022
- Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyAmerican Journal of Clinical Dermatology, 2022
- Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sourcesThe Lancet Regional Health - Europe, 2021
- Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trialJournal of the American Academy of Dermatology, 2020
- Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedJournal of the American Academy of Dermatology, 2019
- Brodalumab: A Review in Moderate to Severe Plaque PsoriasisDrugs, 2018
- The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort StudyArthritis & Rheumatology, 2015
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisNew England Journal of Medicine, 2015